This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
LGND vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Penumbra (PEN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Penumbra (PEN) will likely report strong Neuro sales growth on the strength of its RED 72 (with the proprietary SENDit technology), RED 43 and BMX81.
Why Ligand Pharmaceuticals (LGND) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Will the Medicare Unit Aid Molina Healthcare's (MOH) Q3 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) Q3 results are expected to benefit on growing premiums and an expanding customer base within its Medicaid and Medicare businesses, partly offset by increased medical costs.
What's in Store for Boston Scientific (BSX) in Q3 Earnings?
by Zacks Equity Research
With global staffing issues and the supply situation gradually improving, Boston Scientific's (BSX) international business is expected to have improved further in the third quarter.
What's in Store for Edwards Lifesciences (EW) in Q3 Earnings?
by Zacks Equity Research
Outside the United States, Edwards Lifesciences (EW) TAVR sales growth will likely be driven by broad-based adoption of the SAPIEN platform.
Ligand Pharmaceuticals (LGND) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
In the closing of the recent trading day, Ligand Pharmaceuticals (LGND) stood at $52.09, denoting a -1.31% change from the preceding trading day.
Bio-Rad Laboratories (BIO) to Post Q3 Earnings: What Awaits?
by Zacks Equity Research
Bio-Rad (BIO) Life Science segment will likely have witnessed growth in Q3, driven by Droplet Digital PCR and qPCR products.
Insulet (PODD) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Insulet's (PODD) global new customer starts are expected to have been strong in the third quarter.
GE HealthCare (GEHC) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
GE HealthCare (GEHC) is expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.
Align Technology (ALGN) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Align Technology (ALGN) third-quarter 2023 results are likely to reflect strength in the Clear Aligner business.
Elevance Health (ELV) Q3 Earnings Beat on Carelon Unit Strength
by Zacks Equity Research
Membership growth in the Medicare Advantage business and strong segmental performance aid Elevance Health's (ELV) Q3 results. An encouraging 2023 earnings guidance also bodes well for investors.
Quest Diagnostics (DGX) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Quest Diagnostics (DGX) third-quarter 2023 results are likely to reflect continued strength in the base business.
Elevance Health (ELV) Beats Q3 Earnings, Hikes '23 Profit View
by Zacks Equity Research
Elevance Health's (ELV) Q3 results gain on growing medical customer base and strong pharmacy product revenues. Adjusted net income is currently projected to be more than $33.00 per share for 2023.
Ligand Pharmaceuticals (LGND) Stock Moves -0.47%: What You Should Know
by Zacks Equity Research
In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $54.99, indicating a -0.47% shift from the previous trading day.
Ventyx (VTYX) Down Despite Positive Ulcerative Colitis Study Data
by Zacks Equity Research
Ventyx Biosciences (VTYX) announces positive top-line data from a phase II study evaluating its pipeline candidate, VTX002, for treating moderate-to-severely active ulcerative colitis. Stock down.
LGND vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $58.84, indicating a +1.19% shift from the previous trading day.
Will Ligand (LGND) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Ligand (LGND) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Ligand Pharmaceuticals (LGND) Stock Moves -0.71%: What You Should Know
by Zacks Equity Research
In the latest trading session, Ligand Pharmaceuticals (LGND) closed at $58.75, marking a -0.71% move from the previous day.
Ligand Pharmaceuticals (LGND) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Ligand Pharmaceuticals (LGND) closed at $61.49, marking a +0.03% move from the previous day.
Ligand (LGND) Acquires Certain Assets of Novan for $12.2M
by Zacks Equity Research
Following the acquisition, Ligand (LGND) has full ownership rights to berdazimer gel, all assets related to NITRICIL drug delivery technology platform and rights to the Sitavig program.
Ligand Pharmaceuticals (LGND) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) closed at $59.08 in the latest trading session, marking a -0.4% move from the prior day.